Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a ...
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Novartis seeks to collaborate with Healthcare Professionals and Healthcare Organizations in interest of patients. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals ...
Explore opportunities with Novartis below.
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Shareholders approve all other proposals by the Board of Directors, including the reduction of share capital, the 2025 report on nonfinancial matters and the 2025 Compensation Report, as well as the ...
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ...
Auditoría y Finanzas BD&L & Strategic Planning Communications & Public Affairs Data and Digital Gerencia Comercial y General Instalaciones y Administración Interns/Students on Novartis Payroll Market ...
Asthma affects an estimated 358 million people worldwide and can cause a significant personal, health and financial burden when not adequately controlled 3,4 “Novartis is working to reimagine medicine ...
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results